Table 2A.
HEV T‐Cell Target Mapping to Individual 15 Amino Acid Peptides
| HEV Peptide No. | HEV Peptide Sequence | HEV Peptide Pool | HEV Genome Region | Responding Patient(s) (SFU/106 PBMC) | CD4/CD8 Restriction |
|---|---|---|---|---|---|
| 10 | FLSRLQTEILINLMQ | A | ORF1 | 031 (25) | Un |
| 38 | GFSRCAFAAETGVAL | A | ORF1 | 035 (1370), 043 (295) | CD8 |
| 39 | CAFAAETGVALYSLH | 043 (135) | |||
| 78 | KSTFHAVPVHIWDRL | B | ORF1 | 029 (1098) | CD8 |
| 79 | HAVPVHIWDRLMLFG | 029 (830) | |||
| 113 | LVFDESVPCRCRTFL | C | ORF1 | 030 (50), 031 (1055) | CD8 |
| 114 | ESVPCRCRTFLKKVA | 030 (70), 031 (955) | |||
| 199 | RRLLYTYPDGAKVYA | E | ORF1 | 113 (130) | CD8 |
| 200 | YTYPDGAKVYAGSLF | 113 (95) | |||
| 260 | NGRRVVIDEAPSLPP | F | ORF1 | 029 (93), 035 (105) | CD4 |
| 281 | TSRVLRSLFWNEPAI | F | ORF1 | 043 (118), 109 (80), 110 (98) | CD8 |
| 282 | LRSLFWNEPAIGQKL | 109 (63), 110 (75) | |||
| 328 | CRMAAPSQRKAVLST | G | ORF1 | 029 (205), 034 (75), 042 (30), 047 (25), 029 (198), 110 (100) | Un |
| 329 | APSQRKAVLSTLVGR | ||||
| 330 | RKAVLSTLVGRYGRR | ||||
| 432 | CFCLCCPRHRPASRL | I | ORF3 | 031 (45) | Un |
| 433 | CCPRHRPASRLAVVV | 031 (35) | |||
| 456 | LFFVFLPMLPAPPAG | L | ORF2 | 030 (15), 034 (40) | Un |
| 466 | QPFALPYIHPTNPFA | L | ORF2 | 029 (18), 043 (33), 109 (68), 115 (30), 029 (15) | Un |
| 467 | LPYIHPTNPFAADVV | ||||
| 486 | GAILRRQYNLSTSPL | M | ORF2 | 029 (35), 032 (20), 045 (30), 110 (55) 115 (50), 029 (70), 030 (15), 035 (115), 045 (45), 109 (33), 110(50), 029 (40), 030 (45) | CD4 |
| 487 | RRQYNLSTSPLTSSV | ||||
| 488 | NLSTSPLTSSVASGT | ||||
| 491 | SGTNLVLYAAPLNPL | M | ORF2 | 031 (80), 032 (85) | CD8 |
| 492 | LVLYAAPLNPLLPLQ | 031 (30), 035 (210) | |||
| 514 | ASELVIPSERLHYRN | M | ORF2 | 035 (90), 108 (30), 110 (120) | CD4 |
| 521 | EEATSGLVMLCIHGS | M | ORF2 | 101 (723) | CD8 |
| 525 | VNSYTNTPYTGALGL | M | ORF2 | 030 (110), 031 (523), 045 (60), 047 (340), 101 (53), 113 (55), 030 (90), 031 (525), 045 (30), 101 (65) | CD8 |
| 526 | TNTPYTGALGLLDFA | ||||
| 539 | LTTTAATRFMKDLHF | M | ORF2 | 042 (135) | CD8 |
| 550 | TELISSAGGQLFYSR | N | ORF2 | 035 (290), 108 (40) | CD8 |
| 555 | NGEPTVKLYTSVENA | N | ORF2 | 029 (50) | CD4 |
| 556 | TVKLYTSVENAQQDK | 029 (135) | |||
| 567 | TPSPAPSRPFSVLRA | N | ORF2 | 031 (110), 045 (35) | CD8 |
| 576 | TNPMYVSDTVTFVNV | N | ORF2 | 031 (35) | CD8 |
| 577 | YVSDTVTFVNVATGA | 031 (25) | |||
| 587 | SKTFYVLPLRGKLSF | N | ORF2 | 031 (120) | CD4 |
| 588 | YVLPLRGKLSFWEAG | 031 (40) | |||
| 603 | AVGVLAPHSALAVLE | N | ORF2 | 031 (115) | CD8 |
| 604 | LAPHSALAVLEDTVD | 031 (105) |
Regions of sequence overlap between adjacent peptides are shown underlined.
CD4 or CD8 restrictions were determined by CD8+ depletion ELISpot.
Abbreviation: Un, unknown.